Cello Group Aquires Defined Health
FLORHAM PARK, New Jersey, February 1, 2017
Defined Health announced today that it has been acquired by Cello Group plc (AIM: CLL), a leading global healthcare and consumer strategic marketing group based in London. Under the terms of the acquisition, Defined Health will operate as Defined Health Inc, a wholly owned subsidiary of Cello Health. Defined Health Inc and its full team of employees including all its key principals will become part of Cello Health and its global specialist capabilities in consulting, insight and communications.
Defined Health, founded in 1983, is a leading business development strategy firm servicing life sciences firms with a particular focus in biotech. The firm possesses a unique perspective, grown over decades of evaluating pipeline opportunities. This experience bridges knowledge of clinical practice, drug development, business development and commercial strategy. The concept of Proof of Relevance or PoR, introduced by Defined Health in 2009, has become a cornerstone of strategic thinking in accelerating value for development stage therapies. Defined Health has significant expertise including oncology, orphan and rare diseases, cardiometabolics, neuroscience, and across a multitude of additional therapeutic categories.
Defined Health is an especially strong player in the oncology field. Their annual Cancer Progress conference has been for more than 20 years one of the leading forums for significant dialog among thought leading clinicians, major biopharma companies and prominent investors.
As part of Cello Health, Defined Health will be able to offer greater value to clients through Cello Health’s deeper global network supported by additional highly relevant capabilities, especially in such areas as brand strategy, medical communications, and market access/reimbursement and portfolio optimization.
Ed Saltzman, President and Founder of Defined Health said, “Defined Health has established a leading biopharma consultancy operating at the critically important intersection of science and strategy. Over the years we are proud to have developed a team widely recognized for industry thought leadership and an enviable client roster spanning big pharma to discovery and development stage biotech. Cello Health’s core capabilities both augment and powerfully synergize with our own, and will serve to increase the value we can offer our clients through the full span of the development process from early development to commercial launch. We are extremely excited to be part of Cello Health.”
“We are just as excited to have Defined Health join our Cello Health family with the complementary fit to our consulting, insight and communication capabilities, and our focus on early drug development,” added Julia Ralston, CEO, Cello Health US.